Phase 1 Kidney Cancer Trial, Recruiting NCT05759923 Sponsor: Molecure S.A. Condition: Kidney Cancer
Back to Kidney Cancer

Phase 1 Kidney Cancer Trial, Recruiting

NCT05759923
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand and follow the study requirements
  • People aged 18 or older at the time of screening
  • People with a general health and activity level rated as 0 or 1 on a standard oncology scale, meaning they are either fully active or have minor restrictions in physically strenuous activity (confirm with trial site)
  • People with confirmed advanced and/or metastatic colorectal cancer, kidney cancer, or pancreatic cancer — or returning serous ovarian cancer that has not responded to platinum-based chemotherapy or where platinum-based chemotherapy is not suitable — where the cancer has progressed or come back after at least one previous course of standard cancer treatment
  • People who have provided written consent before any study procedures begin

Who may not be able to join:

  • People who are unable to swallow or take oral (by mouth) medications
  • People with currently active cancer spread to the brain or the lining around the brain or spinal cord
  • People who have had major surgery within 30 days before the first dose of the study drug
  • People who are pregnant or currently breastfeeding
  • People with a known allergy to any of the inactive ingredients in the study drug
  • People with a severe or uncontrolled medical condition that, in the treating doctor's judgment, could put their safety at risk or affect their ability to participate
  • People who have taken part in another clinical trial within 4 weeks before the first dose of the study drug

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0048225526724

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Molecure S.A.
Registry
ClinicalTrials.gov
Start date
26 January 2023
Est. completion
1 December 2025

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

Nature, frequency and severity of adverse events (AEs); Occurence of DLTs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov